Patient Access: Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP

AFTER CONSIDERING THE EFFICACY AND SAFETY OF TREMFYA® FOR YOUR ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY

NATIONALLY, 9 OUT OF 10 COMMERCIALLY INSURED PATIENTS HAVE FIRST-LINE, PREFERRED* ACCESS TO TREMFYA®

The information provided does not imply comparable safety or efficacy between products and only represents access information. Indicated trademarks are the registered trademarks of their respective owners. Please refer to each product’s prescribing information for indication(s), recommended dosing, and administration.

IL=interleukin.

*“Preferred” means TREMFYA® can be accessed first-line and its formulary status is better than or equivalent to other products in the class.

“Best-in-class” means the number of first-line covered lives is greater for TREMFYA® than for other products in the IL-23 inhibitor class (Skyrizi® [risankizumab-rzaa], Ilumya® [tildrakizumab-asmn]).

“Superior” means the number of first-line covered lives is at least 10% greater for TREMFYA® than for products in the IL-17 inhibitor class (Cosentyx® [secukinumab], Taltz® [ixekizumab], Siliq® [brodalumab]).

Collected in May 2022 and is subject to change. This information does not provide advice or guarantee coverage or payment. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply. This may not represent 100% of formulary lives due to data limitations.

Source: Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of May 2022.

LOCAL COVERAGE OPTIONS FOR TREMFYA®

TREMFYA® access has changed in many regions–see where it has preferred first-line access without biologic step edits* by entering a ZIP code below.

 

*Requiring no step edits indicates a drug will be given first-line biologic access and will not require stepping through other biologic therapies.

The information provided is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage, levels of reimbursement, payment, or charge. It is not intended to increase or maximize reimbursement by any payer. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. Please refer to the applicable plan’s website, or contact the plan for more information about coverage or any restrictions or prerequisites that may apply. We strongly recommend you consult the payer organization for its reimbursement policies. All information is subject to change. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Janssen Biotech, Inc.